Delayed Cancer Care Continues to Shape Outcomes in People With HIV
People living with HIV in sub-Saharan Africa face a widening cancer burden, but the evidence base is fragmented across tumor types, treatment settings, and levels of care. A scoping review published in 2026 pulled together 51 reports from ten countries to map how HIV-associated cancers are treated, where outcomes are documented, and which barriers repeatedly interfere with care. The review covered Kaposi sarcoma, cervical cancer, lymphoma, breast cancer, and a smaller set of other cancers or mixed populations.
The clinical picture that emerges is not one of a single therapeutic failure. It is a chain of failures: late presentation, incomplete access to therapy, high out-of-pocket costs, toxicity, interruptions in treatment, and follow-up loss. Each weak link can erode the chance that chemotherapy, radiotherapy, surgery, or combined treatment will translate into durable control of malignancy.
What the Scoping Review Captured Across Ten Countries
Investigators searched MEDLINE via PubMed, CINAHL, EBSCO, Google Scholar, African Journals Online, and ClinicalTrials.gov for relevant interventional studies. The review did not attempt a pooled efficacy estimate, which would have been misleading across highly heterogeneous cancers, regimens, and health systems. Instead, it charted treatment approaches, outcomes, HIV care features, barriers to delivery, and proposed service strategies, then interpreted the literature with methodological quality tools from the Critical Appraisal Skills Programme.
The included evidence was uneven by cancer type. There were 13 reports on Kaposi sarcoma, 13 on cervical cancer, 11 on lymphoma, eight on breast cancer, and six reports spanning other cancers or mixed cohorts. Some cohorts described tumor response or survival after active cancer therapy, but those data were not consistent enough to support a single narrative across all settings. Associations between HIV status and survival varied by cancer and by location, suggesting that the same diagnosis can carry very different prognostic meaning depending on when patients arrive and whether care can be completed.
Survival Depends on Access to the Entire Treatment Pathway
The most striking pattern in the review is how often outcomes were constrained before treatment could be delivered at full intensity. Delayed diagnosis means patients enter care with more advanced disease, which narrows the effect size of any therapy. Limited treatment capacity can delay initiation of chemotherapy or radiotherapy, while travel expenses and direct treatment costs can make continuation impossible for families already under financial strain.
Interrupted treatment matters biologically as well as logistically. Malignancies such as lymphoma and cervical cancer depend on sustained therapy delivery for optimal cytoreduction, and interruptions can permit residual disease to regrow between cycles or sessions. In settings where toxicity management is limited, patients may also stop therapy early because manageable adverse effects become clinically destabilizing when laboratory monitoring, antiemetics, transfusion support, or infection prevention are incomplete.
One consequence is difficult to ignore: outcomes reported from carefully selected treatment cohorts may look better than the real-world experience of patients who never complete therapy.
HIV-Specific Outcomes Remained Inconsistently Reported
A major limitation across the literature was the inconsistent reporting of HIV-specific outcomes. Some studies combined participants with and without HIV, which made it impossible to isolate results for people living with HIV alone. In other studies, HIV status was recorded, but follow-up metrics were incomplete or defined differently across reports. The result is a body of evidence that describes cancer treatment in HIV-affected populations without always being able to measure the HIV-related component cleanly.
This is not a minor reporting issue. HIV-related immunosuppression, antiretroviral use, drug interactions, and vulnerability to infection can all alter cancer treatment tolerance and survival. Without consistent stratification, clinicians cannot tell whether a worse outcome reflects tumor biology, treatment interruption, advanced disease at presentation, or the interaction between cancer therapy and HIV disease control.
Care Coordination Emerged as a Recurrent Strategy, But Few Interventions Were Tested
Across the reviewed reports, care coordination and patient support were repeatedly proposed as ways to improve completion and survival. The idea is clinically sound: integrated HIV-oncology care can reduce referral delays, align antiretroviral therapy with cancer treatment, and improve monitoring for toxicity or opportunistic infection. Supportive services can also address transportation barriers, medication access, and follow-up retention.
Yet the review found few comparative evaluations of these strategies. That leaves practice dependent on face validity rather than direct evidence. Clinicians can see why a navigated, coordinated model should help, but the literature still does not identify which service configurations produce the best outcomes, for which cancers, or in which health systems. A practical intervention may exist; proof of comparative benefit remains thin.
Why the Evidence Base Still Leaves Clinicians Without Firm Answers
The review’s value lies in exposing how much of the current literature stops short of the point that matters most: whether people living with HIV complete treatment and survive longer when care is organized differently. Because the included studies varied by cancer type, therapy, setting, and measurement, pooled outcomes could not be attributed confidently to HIV-positive patients alone. CASP appraisal helped frame the quality of the evidence, but it could not correct the underlying heterogeneity.
From a bedside perspective, the findings reinforce several priorities. Cancer care for people with HIV in sub-Saharan Africa has to begin early, before disease burden becomes overwhelming. Treatment should be delivered in a way that reduces missed visits and unnecessary interruption. HIV and oncology services need closer coordination so that antiretroviral therapy, cancer therapy, infection prevention, and toxicity surveillance are handled as one clinical pathway rather than separate systems.
A single theme ran through the review: outcomes are shaped as much by access and continuity as by the anticancer regimen itself.
Diagnosis-Time Studies and Comparative Service Trials Are the Next Step
The authors call for studies that begin at diagnosis and follow patients through treatment completion and survival, rather than starting with cohorts already selected for having reached care. That design would better capture the full effect of diagnostic delay, treatment drop-off, toxicity, and loss to follow-up. Comparative evaluations of service interventions are also needed, because coordinated care is repeatedly recommended but rarely tested head-to-head against usual practice.
The prospective protocol registration on the Open Science Framework adds transparency to the review process, but it does not solve the central evidence gap. What remains missing are rigorous studies that measure whether specific models of integrated HIV-cancer care can improve treatment completion, reduce interruptions, and extend survival across the cancers that dominate the regional burden.